Glaukos Corporation (NYSE:GKOS) Given Consensus Rating of “Moderate Buy” by Analysts

Glaukos Corporation (NYSE:GKOS) has earned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $149.1667.

GKOS has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Glaukos from a “buy” rating to a “hold” rating in a research note on Sunday, June 21st. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Stifel Nicolaus set a $170.00 target price on shares of Glaukos in a research note on Thursday, April 30th. BTIG Research reiterated a “buy” rating and issued a $162.00 target price on shares of Glaukos in a research note on Wednesday, June 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Leana Wen sold 1,700 shares of Glaukos stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the sale, the director directly owned 19,739 shares in the company, valued at approximately $2,829,585.65. The trade was a 7.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. The trade was a 12.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 41,273 shares of company stock valued at $5,832,003. 5.90% of the stock is currently owned by insiders.

Institutional Trading of Glaukos

Institutional investors and hedge funds have recently bought and sold shares of the business. First Horizon Corp lifted its stake in Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Glaukos during the 4th quarter valued at approximately $28,000. Larson Financial Group LLC lifted its stake in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares during the period. Parallel Advisors LLC lifted its stake in Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 226 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in Glaukos by 111.4% during the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 215 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Up 1.3%

GKOS stock opened at $144.37 on Friday. The firm has a 50 day moving average of $127.29 and a 200 day moving average of $118.14. The stock has a market capitalization of $8.48 billion, a PE ratio of -44.02 and a beta of 0.82. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10. Glaukos has a 52 week low of $73.16 and a 52 week high of $148.11.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. Glaukos’s revenue for the quarter was up 41.2% on a year-over-year basis. During the same period last year, the business earned ($0.22) EPS. Sell-side analysts forecast that Glaukos will post -0.57 earnings per share for the current year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.